Pular para o conteúdo

Katharina Höfer recebe o Prêmio Otto Meyerhof da GBM e Boehringer Ingelheim

A Dra. Katharina Höfer recebeu o Prêmio Otto Meyerhof da Sociedade de Bioquímica e Biologia Molecular (GBM) no âmbito do 75º Colóquio de Mosbach da GBM. O prêmio, no valor de 5.000 euros, cujo valor em dinheiro é doado pela Boehringer Ingelheim Pharma, foi concedido pela sexta vez e homenageia jovens cientistas notáveis que pesquisam na Alemanha e trabalham em uma área relevante para a GBM em bioquímica e biologia molecular. Ele homenageia o fisiologista e bioquímico de renome mundial Otto Meyerhof, que trabalhou em Kiel, Berlim e Heidelberg, de onde teve que fugir como cientista judeu em 1938. A entrega do Prêmio Otto Meyerhof, no valor de 5.000 euros, a Katharina Höfer ocorreu em 22 de março de 2024, no âmbito do 75º Colóquio de Mosbach da GBM. Assim como nos anos anteriores, o prêmio em dinheiro foi doado pela empresa Boehringer Ingelheim Pharma. Mais informações: https://gbm-online.de

Diretrizes da Sociedade Chinesa de Cardiologia sobre o diagnóstico e tratamento da miocardite fulminante em adultos

Recently, the Wang Dao Wen’s team of Huazhong University of Science and Technology published a paper titled “ Chinese Society of Cardiology guidelines on the diagnosis and treatment of adult fulminant myocarditis”. This is the first release of diagnostic and treatment guidelines for adult fulminant myocarditis in China. This guideline points out that the cytokine storm caused by the excessive activation of innate immunity and the rapid release of inflammatory factors by immune cells, also known as the „inflammatory storm“, is the core cause of the rapid onset, rapid progression, severe condition, and high mortality rate of fulminant myocarditis. It systematically summarizes the clinical evaluation content of patients with fulminant myocarditis from the collection of medical history, clinical symptoms, and related examinations, Thus, the clinical diagnostic criteria and diagnostic process for fulminant myocarditis were established, and a “life support-based comprehensive… 

more »Chinese Society of Cardiology guidelines on the diagnosis and treatment of adult fulminant myocarditis

Vielversprechende Medikamentenkombination zur Behandlung des multiplen Myeloms

  • Geral

25. März 2024: RCSI-Forschungen haben ergeben, dass Venetoclax, ein derzeit gegen Leukämie zugelassenes Medikament, Vorteile für Patienten mit multiplem Myelom hat, wenn es in Kombination mit einem anderen Medikament angewendet wird. Diese Entdeckung eröffnet neue Möglichkeiten zur Behandlung der derzeit unheilbaren Krankheit. Das Multiple Myelom (MM) ist eine Blutkrebsart, die in Irland jedes Jahr bei etwa 400 Menschen neu diagnostiziert wird. Trotz der Fortschritte in der Behandlung in den letzten Jahren ist sie nach wie vor unheilbar. Die Suche nach innovativen Behandlungsstrategien ist von entscheidender Bedeutung, insbesondere für Patienten, deren Krebs gegen die Standardbehandlung resistent ist. In der neuen, in Haematologica veröffentlichten Studie machten sich Forscher der RCSI-Abteilung für Physiologie und Medizinische Physik und des Beaumont RCSI Cancer Center daran, komplementäre Medikamente zu identifizieren, die die Wirksamkeit von Venetoclax, einem zur Verwendung bei Leukämie zugelassenen Medikament, für die MM-Behandlung verbessern… 

more »Vielversprechende Medikamentenkombination zur Behandlung des multiplen Myeloms

Produtos químicos domésticos: perigo para o cérebro

  • Geral

Ein Forscherteam der  Case Western Reserve University School of Medicine  hat neue Einblicke in die Gefahren einiger gängiger Haushaltschemikalien für die Gehirngesundheit geliefert. Sie legen nahe, dass Chemikalien, die in einer Vielzahl von Gegenständen enthalten sind, von Möbeln bis hin zu Haarprodukten, mit neurologischen Erkrankungen wie Multipler Sklerose und Autismus-Spektrum-Störungen in Verbindung stehen könnten. Neurologische Probleme betreffen Millionen von Menschen, aber nur ein Bruchteil der Fälle kann allein auf die Genetik zurückgeführt werden, was darauf hindeutet, dass unbekannte Umweltfaktoren eine wichtige Rolle bei neurologischen Erkrankungen spielen. Die heute in der Fachzeitschrift  Nature Neuroscience veröffentlichte neue Studie ergab, dass einige gängige Haushaltschemikalien speziell die Oligodendrozyten des Gehirns beeinflussen, einen speziellen Zelltyp, der die schützende Isolierung um Nervenzellen erzeugt. Unter der Annahme, dass die Auswirkungen von Chemikalien auf die Gehirngesundheit nicht gründlich genug erforscht wurden, analysierten die Forscher über 1.800 Chemikalien, denen… 

more »Haushaltschemikalien: Gefahr für’s Gehirn

Nucleus Genomics lança para trazer sequenciamento de genoma completo ao público

Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone. DNA and health are inextricably linked, but profound insights into how DNA can shape health are missing from healthcare. Customers who’ve previously done microarray genetic testing with older testing companies can upload their DNA data onto Nucleus’ platform to receive greater insights into their genetic risk for diseases like type 2 diabetes, breast cancer, and many more. Nucleus further personalizes these risk assessments by integrating personal and lifestyle factors into their analysis — such as age, cholesterol levels, blood pressure, and BMI. The company — which raised a total of $18 million in seed funding in 2022 from venture capital firms such as Alexis Ohanian’s Seven Seven Six and Peter Thiel’s Founders Fund… 

more »Nucleus Genomics launches to bring whole-genome sequencing to the public

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 3,054,609 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 3,054,609 shares of Common Stock at a combined offering price of $2.901 per Share and Accompanying Warrant and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 5,565,027 shares of Common Stock and Accompanying Warrants to purchase up to 5,565,027 shares of Common Stock at a combined offering price of $2.900 per share underlying each Pre-Funded Warrant and Accompanying Warrant, which equals the offering price per… 

more »BioXcel Therapeutics Announces $25 Million Registered Direct Offering

A Chemomab recebeu uma nova patente europeia para o CM-101, seu anticorpo monoclonal de primeira classe em desenvolvimento clínico de Fase 2 para Colangite Esclerosante Primária

Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories. Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Starton Therapeutics Apresentará nas Próximas Conferências MedInvest e Needham

PARAMUS, N.J., March 25, 2024 (GLOBE NEWSWIRE) — Starton Therapeutics Inc., (“Starton” or the “Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, today announced that Pedro Lichtinger, Chairman and Chief Executive Officer of Starton Therapeutics, will present and host one-on-one meetings at the MedInvest Biotech & Pharma Investor and 23rd Annual Needham Virtual Healthcare Conferences. Details for the events are as follows: Starton Therapeutics to Present at Upcoming MedInvest and Needham Conferences

Valneva Anuncia Arquivamento do Documento de Registro Universal de 2023 e Formulário 20-F dos EUA

Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.24-0157 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC). Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F